Parse Biosciences, an accessible and scalable single cell sequencing solutions provider, completed the acquisition of Biomage, a data analysis software company. Financial terms were not disclosed. “The combination of Parse’s scalability – which allows for exponentially more experiments than other single cell technologies – and Biomage’s technology to speed analysis is an unbeatable combination that is going to have wide-ranging, positive implications for the single cell community,” Adam Kurkiewicz, Biomage Co-Founder and CEO.